Portfolio

Transforming UK university research into global impact

Meet our companies

The companies we invest in are developing groundbreaking university research into successful businesses, spanning sectors including Life Sciences, AI, Quantum Computing, Advanced Materials, Genomics, CleanTech, Future of Mobility, MedTech and Big Data.

Explore our portfolio

Finger prick blood test for chemo patients
52 North Health is developing the world’s first finger-prick blood test to measure white blood cell count and blood lactate for chemotherapy patients at risk. They create in-vitro diagnostic and digital solutions to improve emergency care.
Institution
Cambridge
  • Digital Health

52 North Health

52 North Health is developing the world’s first finger-prick blood test to measure white blood cell count and blood lactate for chemotherapy patients at risk. They create in-vitro diagnostic and digital solutions to improve emergency care.
Sector
Digital Health
Institution
Cambridge
Website
52north.health

Your Portfolio

If you are an existing investor and want to find out more about your portfolio, visit the investor portal.
Visit Investor Portal

Latest from Parkwalk and our portfolio

17 April 2026

HealthTech portfolio companies feature in Tech Funding News

Portfolio
8 April 2026

K3 Metrology raises £2.75m Seed funding round

Hardware
Portfolio
2 April 2026

Parkwalk’s Northern Universities Venture Fund makes first two investments

Funds
View all Parkwalk and portfolio news

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.